Abstract 937P
Background
Pain, fatigue and depression are commonly seen in cancer survivors and may co-occur. The extent of these symptoms occurring, alone or together, in head and neck cancer (HNC) is unknown. Using data from the Head and Neck 5000 cohort, we (i) investigated prevalence of the pain, fatigue, depression symptom cluster and (ii) explored its association with health-related quality of life (HRQoL).
Methods
Sociodemographic and clinical data were collected from participants at cohort recruitment (pre-treatment). At 12-months post-recruitment, cancer-related pain, fatigue and HRQoL were measured using the EORTC QLQ-C30, and depression using the Hospital Anxiety & Depression Scale (HADS). Cut-offs to define presence of clinically-important symptoms were: pain ≥25, fatigue ≥39 and depression ≥8. Associations between HRQoL score (on scale 1-100; higher score=better HRQoL) and the symptom cluster (0/1/2/3 symptoms), adjusted for clinical and sociodemographic variables, were assessed using multivariate linear regression.
Results
2,207 patients were included in the analysis. 47.3% had one or more symptoms of pain, fatigue or depression at clinically important levels. 20.3% had any one symptom, 13.7% had any two symptoms and 13.4% had all three symptoms. In the multivariate analysis, number of symptoms was strongly associated with HRQoL. After adjusting for other variables, presence of any one symptom was associated with a 13.4 point decrease (95% CI -15.2 to -11.7) in HRQoL, any two symptoms with a 26.3 point decrease (95% CI -28.3 to -24.3) and all three symptoms with a 42.3 point decrease (95% CI -44.3 to -40.2) in the HRQoL.
Conclusions
There is a high prevalence of the pain, fatigue and depression cluster in HNC survivors with over one in ten experiencing all three symptoms at 12-months. They have a significant negative impact on HRQoL. More attention should be given to identifying survivors experiencing this symptom cluster. Interventions targeted at addressing the cluster symptoms may help improve HRQoL amongst HNC survivors.
Clinical trial identification
N/A
Editorial acknowledgement
Funding
National Institute for Health and Care Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03